Detalles de la búsqueda
1.
Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease.
J Clin Gastroenterol
; 50(6): 483-9, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26166141
2.
Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNFα Therapy.
Am J Gastroenterol
; 110(11): 1526-32, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26032156
3.
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab.
Dig Dis Sci
; 60(9): 2762-70, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25673037
4.
Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
Am J Gastroenterol
; 109(7): 1055-64, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24796769
5.
Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
Ther Drug Monit
; 35(4): 530-8, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23765033
6.
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Clin Gastroenterol Hepatol
; 8(7): 600-9, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20117244
7.
Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease.
Inflamm Bowel Dis
; 23(7): 1210-1217, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28445244
8.
Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.
AAPS J
; 19(1): 223-233, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27739011
9.
Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
J Crohns Colitis
; 9(11): 1032-42, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26245216
10.
Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
J Crohns Colitis
; 9(3): 238-45, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25576753
11.
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
Inflamm Bowel Dis
; 18(12): 2209-17, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22344964
12.
Monitoring immunogenicity of protein-based TNF antagonists.
Frontline Gastroenterol
; 7(2): 152-154, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28839850
13.
World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010.
Inflamm Bowel Dis
; 16(1): 112-24, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19653289
14.
Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Am J Gastroenterol
; 97(3): 649-53, 2002 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-11922560
Resultados
1 -
14
de 14
1
Próxima >
>>